Better Discount To Bylvay £255,000 List Price Sways England’s NICE
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
You may also be interested in...
Health technology assessment body NICE has also issued guidances rejecting three products.
The European Medicines Agency has delivered its verdict on the latest medicines it believes should be approved for marketing in the EU. By contrast, it has given the thumbs down to one biosimilar anticancer drug and its duplicate.
Oncopeptides is nearing the end of the regulatory review cycle in the EU for its multiple myeloma drug, melphalan flufenamide. The product has had an erratic journey in the US, where it was approved but then withdrawn, and the withdrawal was subsequently rescinded.